Crescent Biopharma, Inc. (CBIO): Total Assets
$240.29M
As of 2025-12-31
$182.76M
As of 2026-06-30
+66.8%
3-year compound annual growth
+11.0%
5-year compound annual growth
+17.4%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $240.29M | +574.7% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $35.62M | -21.4% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $45.32M | -12.5% | 2025-02-13, Balance as of period end |
| 2022-12-31 | $51.81M | -45.1% | 2024-03-27, Balance as of period end |
| 2021-12-31 | $94.35M | -33.9% | 2023-03-29, Balance as of period end |
| 2020-12-31 | $142.83M | -15.0% | 2022-03-03, Balance as of period end |
| 2019-12-31 | $167.97M | -21.8% | 2021-03-02, Balance as of period end |
| 2018-12-31 | $214.84M | +67.1% | 2020-02-28, Balance as of period end |
| 2017-12-31 | $128.58M | +203.3% | 2019-03-06, Balance as of period end |
| 2016-12-31 | $42.39M | -12.5% | 2018-03-06, Balance as of period end |
| 2015-12-31 | $48.46M | -15.4% | 2017-03-01, Balance as of period end |
| 2014-12-31 | $57.26M | +983.8% | 2016-02-29, Balance as of period end |
| 2013-12-31 | $5.28M | n/a | 2015-03-16, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Crescent Biopharma, Inc. (CBIO) | 2025-12-31 | $240.29M | +574.7% |
| Jaguar Health, Inc. (JAGX) | 2025-12-31 | $38.32M | -28.3% |
| Janux Therapeutics, Inc. (JANX) | 2025-12-31 | $1.00B | -5.6% |
| Zenas BioPharma, Inc. (ZBIO) | 2025-12-31 | $383.64M | +3.7% |
| Prelude Therapeutics Inc (PRLD) | 2025-12-31 | $141.31M | -19.5% |
| Precigen, Inc. (PGEN) | 2025-12-31 | $155.50M | +7.0% |
| Prothena Corp Public Ltd Co (PRTA) | 2025-12-31 | $326.80M | -40.3% |
| Emmaus Life Sciences, Inc. (EMMA) | 2025-12-31 | $21.44M | -9.2% |
| International Stem Cell Corp (ISCO) | 2025-12-31 | $4.82M | -6.8% |
Compare CBIO, JAGX, JANX, ZBIO side by side · Screen every company in Pharmaceutical Preparations ↗